1049666-34-3

Basic information

• Product Name: 2-chloro-5-fluoro-N-(4-fluorophenyl)pyrimidin-4-amine
• Synonyms: 2-chloro-5-fluoro-N-(4-fluorophenyl)pyrimidin-4-amine
• CAS NO: 1049666-34-3
• Molecular Weight: 241.628
• Mol File: 1049666-34-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-chloro-5-fluoro-N-(4-fluorophenyl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-fluoro-N-(4-fluorophenyl)pyrimidin-4-amine(1049666-34-3)
• EPA Substance Registry System: 2-chloro-5-fluoro-N-(4-fluorophenyl)pyrimidin-4-amine(1049666-34-3)

Safety Data

• Hazardous Substances Data: 1049666-34-3(Hazardous Substances Data)

Upstream product

• 2927-71-1 2,4-dichloro-5-fluoropyrimidine 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1049666-35-4 (5-fluoro)-N*4*-(4-fluorophenyl)-N*2*-phenyl-pyrimidine-2,4-diamine 

Relevant articles and documents

Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9

Based on a 3D-QSAR pharmacophore derived from a diverse set of known cyclin-dependent kinase 9 (CDK9) inhibitors and a composite pharmacophore extracted from the complex structure of flavopiridol (FVP)-CDK9, thirty novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamine derivatives were designed and synthesized. Initial tests against four tumor cell lines with the sulforhodamine B (SRB) assay identified a series of potent compounds with GI50 values at a lower micromolar or submicromolar level. Most of the highly cytotoxic compounds exhibited potent inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. Notably, inhibitions against the two enzymes were generally correlated well with the cytotoxicity of these compounds. Appreciable inhibition was also observed for selected compounds in the anti-HIV-1 assay. Docking studies on compounds 6d and 9g provided conducive clues to further structural optimization. This journal is

N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditio